All News
Best of 2020: The COVID-19 Global Rheumatology Registry
What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease and guide clinicians in assessing and treating patients.
Read Article
Best of 2020: A Rheumatologist’s Tips: Telemedicine in 6 Easy Steps
Ready for telemedicine/telerheumatology?
Once you and your patient agree on a virtual visit, the following suggestions may help facilitate the interaction. If you have the ability and the capacity, record the visit.
#BestACR20Tweets
Cohort study from NYC shows that patients w/COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressive https://t.co/9mnb05Xqfa
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
Racial/ethnic minorities with rheum Dz(RD) & COVID had increased odds of hospitalization & vent support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital https://t.co/Aa5UHwvXTA https://t.co/cFk8z8p985
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/0kiJpq46pE https://t.co/iQHGE47Hfd
Links:
Dr. John Cush RheumNow ( View Tweet)
#Bestof2020 The COVID-19 Global Rheumatology Registry by Dr. Kathryn Dao ( @KDAO2011)
https://t.co/fmAbFYtLQ8 https://t.co/EQE0Cp14zZ
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @drpnash : Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/bSkedaRwfv #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
Links:
Dr. John Cush RheumNow ( View Tweet)
The core problem of COI amongst docs is that the profession does not really care. Disclosure is not the solution. Divestment and recusal are, but no one inside wants to do that.
This was a case of failure to disclose (on a large scale) and the punishment was a promotion https://t.co/Q384TNnPy2
Vinay Prasad VPrasadMDMPH ( View Tweet)
#BestACR20Tweet
RT @KDAO2011 : Abstr#0545 TCZ and Tofa may be safe in patients with resolved Hepatitis B infection. MGH study of 20 pts given TCZ or Tofa, followed 4 years; 25% on antivirals, but no cases of transaminitis from HBV or reactivation of HBV seen.
#ACR20 @rheumnow
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Abstr#0013 TEASER! Colchicine may improve COVID19 outcomes in hospitalized patients. 50 pts 1:1 colchicine vs. PCB + standard of care: Colchicine group 2X more likely to be d/c from hospital, and less likely to die. Larger studies needed! #ACR20
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : #ACR20 Abstr#0431 Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients @rheumnow https://t.co/7yn0fK1tfn
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @uptoTate : Claims-based "big data" reveals PsA pts had "arthritis" coding prior to formal dx and coding for enthesitis, axial dz, and arthritis increased prior to PsA dx. Coding diff between treating specialties also noted. #ACR20 https://t.co/naeRPFZdap https://t.co/E4XvlZSsX6
Links:
Dr. John Cush RheumNow ( View Tweet)
Content Download Available! Download our document on arthritis myths below.
https://t.co/2Kxpou4Fbz https://t.co/iPIqR92ME1
Links:
Dr. John Cush RheumNow ( View Tweet)
#Bestof2020: A Rheumatologist’s Tips: Telemedicine in 6 Easy Steps
https://t.co/p8B0dDTktT https://t.co/sHBisreYnW
Links:
Dr. John Cush RheumNow ( View Tweet)
#Bestof2020: Rheumatic Disease Drugs and COVID-19
https://t.co/82uGbNqm9R https://t.co/U0WyTL5kYZ
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR20 Mid Meeting Recap: Gout
https://t.co/MhaYjotrmb https://t.co/R4dOrSlFl6
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @uptoTate :Dactylitis is a clinical indicator for an aggressive phenotype of PsA categorized w/ significantly greater TJC, SJC, CRP, US synovitis/erosions in very early DMARD naïve pts. #ABS0312 #ACR20 https://t.co/d2ZjXRgvkE https://t.co/60n5pNfx9O https://t.co/EvsR0aJtXJ
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway : Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/yqV6BoKy4s https://t.co/7jUASw5D2f
Links:
Dr. John Cush RheumNow ( View Tweet)
Make sure you check out the RheumNow podcast on Soundcloud or Apple/Android devices. New episodes every week!
https://t.co/wjBWCrKL34 https://t.co/3z2aWfB95V
Links:
Dr. John Cush RheumNow ( View Tweet)